Today: 19 April 2026
Subscribe
Browse Category

NYSE:BSX 22 October 2025 - 25 December 2025

Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target as Valuation Debate Intensifies on Dec. 19, 2025

Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target as Valuation Debate Intensifies on Dec. 19, 2025

Boston Scientific shares traded at $95.76, down 0.36% as of 17:30 UTC Friday, after opening at $96.85 and moving between $95.64 and $97.24. The session coincided with December options expiration, with $7.1 trillion in contracts set to expire. UBS reiterated a Buy rating and $140 target, while Truist cut its target to $120. Trading volume Thursday reached 15.6 million shares, well above the 50-day average.
19 December 2025
·
Boston Scientific (BSX) Stock After Hours Dec. 18, 2025: Analyst Targets Shift, Options Point to Key Levels, and What to Watch Before Friday’s Open

Boston Scientific (BSX) Stock After Hours Dec. 18, 2025: Analyst Targets Shift, Options Point to Key Levels, and What to Watch Before Friday’s Open

Boston Scientific closed Thursday at $96.11, up 1.73%, with trading volume of 15.6 million shares, well above its 50-day average. After-hours trading was steady, with shares at $96.18 as of 6 p.m. ET. Truist Securities lowered its price target to $120 from $130 but kept a Buy rating. The stock remains 12.23% below its 52-week high of $109.50.
19 December 2025
·
Boston Scientific (BSX) Stock After Hours on Dec. 17, 2025: Analysts Stay Bullish as Shares Close Higher — What to Watch Before Thursday’s Open

Boston Scientific (BSX) Stock After Hours on Dec. 17, 2025: Analysts Stay Bullish as Shares Close Higher — What to Watch Before Thursday’s Open

Boston Scientific shares closed up 1.65% at $94.48 on Wednesday, outperforming the broader market as the S&P 500 fell 1.16%. The stock traded as high as $95.99 intraday and saw volume above its 50-day average. After-hours, BSX edged up to $94.70. The stock remains about 13.7% below its 52-week high set in September.
18 December 2025
·
Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target, RBC Raises to $130 as 2026 Catalysts Come Into Focus

Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target, RBC Raises to $130 as 2026 Catalysts Come Into Focus

UBS reiterated a Buy rating on Boston Scientific, keeping its $140 price target and citing upside potential into 2026. RBC raised its target to $130, while Canaccord Genuity adjusted to $131. BSX shares opened near $92.93, down about 10% in a month, with a market cap around $138 billion. Analysts point to growth in cardiac devices but warn on valuation and policy risks.
17 December 2025
·
Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

Boston Scientific shares closed at $92.53 on December 9, down 1.4% and marking a seventh straight decline, with trading volume spiking to 12.7 million shares. The stock sits about 15% below its September high despite strong Q3 results, including 20% year-over-year sales growth and adjusted EPS of $0.75, beating forecasts. Over the past year, BSX remains slightly positive and is up about 170% over five years.
10 December 2025
··
Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets

Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets

Boston Scientific (BSX) closed at $98.57 on December 3, down slightly, with shares trading in a $97.60–$99.30 range. EVP Arthur Butcher sold 17,313 shares on December 1 for about $1.76 million under a pre-arranged plan. The stock is up roughly 8–9% over the past year but remains about 9.6% below its September high. The company also received new European device approvals this week.
4 December 2025
·
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific (BSX) Stock Today: Price Slips as Neuromodulation Bull Case, Epic EHR Deal and Big Fund Moves Shape the Outlook – November 19, 2025

Boston Scientific shares fell 2.6% to $96.60 in late trading Wednesday, extending a three-day slide despite new research highlighting neuromodulation growth and recent acquisitions. The stock remains in the upper half of its 52-week range, with a market cap near $145–150 billion and trading at about 53 times trailing earnings.
19 November 2025
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

U.S. stock indexes hover near record highs after the Dow gained 0.5% Tuesday, while the Nasdaq slipped 0.2% on tech earnings misses. About 85% of S&P 500 companies have beaten forecasts, the highest rate in four years. AMD surged to record highs on AI chip deals, while Eli Lilly hit $935 on obesity drug demand. Netflix fell 6–7% pre-market after an earnings miss; Texas Instruments dropped nearly 9% on weak guidance.
22 October 2025
···········
1 2

Stock Market Today

  • ATI Share Price Surges 262% in One Year, But Valuation Flags Overvaluation
    April 18, 2026, 9:38 PM EDT. Shares of ATI have surged 261.9% over the past year to close at $164.66, fueled by interest in its Aerospace & Defense role. Despite strong gains, ATI scores 0 out of 6 on valuation checks. A Discounted Cash Flow (DCF) model estimates ATI's intrinsic value at approximately $142.92 per share, suggesting the stock is overvalued by 15.2%. The DCF uses projected free cash flows rising from $362.7 million to $1.19 billion by 2035. Investors are questioning whether current prices reflect fundamentals or if sentiment has outpaced growth prospects. Price-to-Earnings (P/E) ratios remain a quick gauge of value, linking share price to current earnings, but must account for growth and risk outlooks. ATI's elevated valuation hints at potential risks despite stellar price momentum.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop